The United States is set to begin phasing out its financial support for Namibia’s HIV response, marking a major shift in the country’s long-standing reliance on American health assistance. Under the transition plan, Namibia will receive $45 million in US funding for its HIV programmes during the 2027 fiscal year. After that, the country is expected to take greater responsibility for financing its HIV response, while US involvement will shift primarily to technical support. The funding has largely come through the President’s Emergency Plan for AIDS Relief (PEPFAR), one of the world’s largest programmes supporting the fight against HIV and AIDS. The US says it has contributed more than $1.1 billion to Namibia’s HIV response since 2003, with annual support in recent years standing at about $45 million.
A new era of health financing The transition comes as the US administration moves towards reducing long-term dependence on American foreign aid and encouraging countries to finance more of their own healthcare programmes.
However, Namibia’s move away from US financial support also comes against the backdrop of a disagreement over proposed health data-sharing arrangements. Namibia had rejected provisions that would have involved sharing health data and biological specimens with the United States, citing concerns around patient privacy, national sovereignty and compliance with its laws. Both countries are now reported to be working towards a new bilateral health agreement. Despite the funding transition, Namibia enters this new phase with significant progress in its HIV response. According to the joint statement from the two governments, 96% of people living with HIV in Namibia know their status, 98% of those diagnosed are receiving treatment, and 98% of people on treatment have achieved viral suppression. These figures put the country above key international HIV targets. What happens next?
The end of direct US financial support will test Namibia’s ability to sustain those gains through domestic resources.
For the Namibian government, the transition presents both a challenge and an opportunity. Increased domestic financing could give the country greater control over its HIV programmes and reduce dependence on external donors. But replacing tens of millions of dollars in annual assistance will require sustained government commitment, particularly to ensure that testing, treatment and prevention services remain accessible.
Namibia is not alone. The US has also begun reducing HIV-related support to other African countries, including South Africa, signalling a broader restructuring of American health assistance across the continent. For Namibia, therefore, the next chapter of its HIV response will be about more than replacing $45 million. It will be about whether the country can build a self-sustaining health system capable of protecting the progress it has made over more than two decades of international support.